Noticias Immuneering Corporation - IMRX | Acciones NASDAQ

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified...

Form 8-K - Current report

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line...

Form 4 - Statement of changes in beneficial ownership of securities

Immuneering Launches Pancreatic Cancer Advisory Board

- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows...

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxe...

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune...

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage...

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with...

Form 8-K - Current report

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

- Immuneering recently announced positive initial Phase 2a data, including complete and partial responses, with...

Form 8-K/A - Current report: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

axelvento 2 días hace

MEK inhibitor IMM-1-104 shows promise in pancreatic cancer: Data

One person saw a 100% reduction in their tumor, which Zeskind said is “a rare event in this patient population.”

As of a cut-off date of Dec. 5, the three trial arms involving pancreatic cancer patients had enrolled more than 75 participants. The recent analyses included patients who had received their first dose of treatment at least 14 weeks before the cut-off.

In one trial arm, participants were given first-line treatment with daily IMM-1-104 (240 or 320 mg) along with a modified regimen of gemcitabine with nab-paclitaxel (GnP), a standard chemotherapy regimen used in pancreatic cancer.

Data showed that the overall response rate (ORR) was 43%, with three of seven treated patients achieving partial or complete cancer shrinkage. Six of the seven participants (86%) achieved controlled disease, where the cancer has shrunk or remained stable. Benchmark data from a Phase 3 trial testing mGnP alone as a first-line pancreatic cancer treatment was associated with an ORR of 23% and a disease control rate 48%.

In another arm, patients were treated with a combination of daily IMM-1-104 (240 mg) along with a modified regimen of FOLFIRINOX as a first-line treatment. FOLFIRINOX is a combination of four chemotherapy agents – leucovorin (folinic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin.

All four evaluable patients achieved a shrinkage of their target tumors and disease control.
The final arm of the Phase 2b trial tested once daily IMM-1-104 monotherapy (320 mg) as a second-line treatment in pancreatic cancer patients. Results showed that 11 of 21 treated patients achieved disease control, including ten people with stable disease and one person who experienced a 67% shrinkage in their target tumor.

The therapy showed a good tolerability profile across treatment arms, with common side effects including diarrhea, fatigue, and nausea.

“Having demonstrated compelling activity in both the combination and monotherapy settings for pancreatic cancer, the emerging tolerability profile for IMM-1-104 is also highly promising,” said Brett Hall, PhD, chief scientific officer of Immuneering. “The maturing safety profile for IMM-1-104 gives us confidence that Immuneering may have developed a better tolerated MEK-inhibitor,” Hall said.

https://rarecancernews.com/news/mek-inhibitor-imm-1-104-shows-promise-pancreatic-cancer-data/

💪 1 💯 1

axelvento 4 días hace

news- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer -

https://ir.immuneering.com/news-releases/news-release-details/immuneering-provides-positive-update-phase-2a-arm-studying-imm-1

👍️0

georgie18 4 días hace

👍️0

georgie18 1 semana hace

Yup...until they get bought out...🥳...imo...we shall see...

👍️0

tw0122 1 semana hace

Added $2.02 but warned folks this is traditional on this stock with news get out premarket add some back on post news beat down

👍️0

georgie18 1 semana hace

👍️0

georgie18 1 semana hace

👍️0

Invest-in-America 1 semana hace

IMRX: Yep, they like to do stuff like that! (Glad I grabbed some @HOTH, when it suddenly popped-up at the bottom of Benzinga's cute little Pre-Market list!!)

👍️0

tw0122 1 semana hace

One more round back in at $2.60s they always beat this one down at market bell and you have to look for the beat down price lol. Second round not as profitable but take it

👍️0

axelvento 1 semana hace

$IMRX reported Phase 2a data for IMM-1-104 in pancreatic cancer, showing 43% ORR and 86% DCR in 1st-line Gemcitabine/nab-paclitaxel combo, with tumor shrinkage in all patients on FOLFIRINOX combo, and 52% disease control in 2nd-line monotherapy. Favorable safety profile supports its potential as a better-tolerated MEK inhibitor for RAS-driven tumors. Further combination data expected in 2Q 2025.

👍️ 1 💯 1

Invest-in-America 1 semana hace

IMRX: WOW!!

👍️0

georgie18 1 semana hace

👍️0

georgie18 1 semana hace

Nice...🥳...I am holding 1/2 for now...

👍️0

georgie18 1 semana hace

Nice to log on and see this move...🥳

👍️0

tw0122 1 semana hace

Rest out $4s hit 4.12

👍️0

georgie18 1 semana hace

IMRX $3.08 Dr. Zeskind continued: “Today we are also sharing initial data from IMM-1-104 in combination with modified FOLFIRINOX in first-line pancreatic cancer patients. We observed target lesion shrinkage across all evaluable patients, including a 100% reduction, a rare event in this patient population. Additionally, we are reporting initial data from our monotherapy arm of IMM-1-104 in second-line pancreatic cancer. We saw clear activity, including a partial response with a 67% target lesion reduction. We believe these results provide substantiating evidence of IMM-1-104’s contribution in combination with current therapies.”

👍️0

tw0122 1 semana hace

News out $3.20s + 34% - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction

👍️0

georgie18 2 semanas hace

IMRX...$2.52...Off the $1.52 Gap Fill Alert...🥳

georgie18

Member Level
Re: georgie18 post# 103

Friday, January 03, 2025 2:26:33 PM

Post#
105
of 105
IMRX...$2.37...🥳...Trying for Upper Bollie Breakout here...Off the $1.52 Gap Fill Alert...

georgie18

Member Level
Re: georgie18 post# 387313

Friday, December 20, 2024 1:41:08 PM

Post#
387324
of 387978
IMRX...$2.08...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 100

Friday, December 20, 2024 12:44:19 PM

Post#
102
of 102
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

👍️0

georgie18 2 semanas hace

IMRX...$2.37...🥳...Trying for Upper Bollie Breakout here...Off the $1.52 Gap Fill Alert...

georgie18

Member Level
Re: georgie18 post# 387313

Friday, December 20, 2024 1:41:08 PM

Post#
387324
of 387978
IMRX...$2.08...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 100

Friday, December 20, 2024 12:44:19 PM

Post#
102
of 102
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

👍️0

glenn1919 4 semanas hace

IMRX......................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783

👍️0

georgie18 4 semanas hace

IMRX...$2.08...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 100

Friday, December 20, 2024 12:44:19 PM

Post#
102
of 102
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

👍️0

georgie18 4 semanas hace

IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

👍️0

axelvento 1 mes hace

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

https://www.biospace.com/press-releases/immuneering-to-present-data-from-three-arms-of-its-ongoing-phase-2a-trial-of-imm-1-104-in-early-january-2025

👍️ 1 🔝 1

georgie18 1 mes hace

IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

👍️0

georgie18 1 mes hace

IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

👍️0

georgie18 1 mes hace

IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

👍️0

Invest-in-America 1 mes hace

IMRX: Thanks, Homeboy Glenn!!

👍️0

glenn1919 1 mes hace

imrx............................https://stockcharts.com/h-sc/ui?s=imrx&p=W&b=5&g=0&id=p86431144783

👍️0

tw0122 1 mes hace

Granted melanoma FDA fast track $2.40s

👍️0

glenn1919 1 mes hace

IMRX...........................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 1 mes hace

IMRX.....https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783

👍️0

georgie18 2 meses hace

I think it will run again...Have to see how the Chart sets up and there is an open gap in the $1.50 range...🥳

👍️0

BurgerKing82 2 meses hace

Could run again soon?

👍️0

glenn1919 2 meses hace

IMRX.....................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 2 meses hace

IMRX.........................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783

👍️0

georgie18 2 meses hace

Yes...I know IMRX well...Good grab...🥳

👍️0

tw0122 2 meses hace

In some again 21m float $1.76 has enough cash to fund operations through 2025. Based on cash, cash equivalents and marketable securities as of September 30, 2024, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into the fourth quarter of 2025. Positive developments ..
- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients -- Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer -

- Initial Data From At Least One Additional Arm of the Phase 2a Portion of the IMM-1-104 Phase 1/2a Trial Expected by Year End -- Cash Runway into Fourth Quarter 2025 - CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided business updates.“We were extremely pleased to share positive initial response data in September for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in pancreatic cancer as part of the ongoing Phase 2a clinical trial,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. “While still early, it is highly encouraging to already see responses – including a complete response – as well as impressive disease control, both at levels that would represent a meaningful improvement over the existing standard of care. If these results continue, we believe we will have a clear path forward for clinical development of IMM-1-104 in combination with gemcitabine/nab-paclitaxel for pancreatic cancer. Importantly, our recent Fast Track and Orphan Drug designations from the FDA may help advance development of this potentially important new therapy for the treatment of pancreatic cancer. With enrollment progressing well in our Phase 2a arms, we expect to share further data by year end and we look forward to providing updates on our progress at that time.”Corporate HighlightsFDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer: In October 2024, the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to IMM-1-104 in the treatment of pancreatic cancer.
Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients: In September 2024, Immuneering announced positive initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first line pancreatic cancer as part of its ongoing Phase 2a clinical trial. If the early trends with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel continue, management believes there is a clear path forward for clinical development of IMM-1-104 in pancreatic cancer, which has the potential to improve the prognosis for a drastically underserved patient population.
FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer: In July 2024, the FDA granted Fast Track designation for IMM-1-104, as a first-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC).
Near-Term Milestone Expectations IMM-1-104Initial data from at least one additional arm of the Phase 2a portion of the Company’s Phase 1/2a trial is expected by year end.
IMM-6-415Initial PK, PD and safety data from the Phase 1 portion of the Company’s Phase 1/2a trial is expected by year end.
Third Quarter 2024 Financial Highlights Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2024 were $50.7 million, compared with $85.7 million as of December 31, 2023. The September 30, 2024 figure includes $4.2 million of net proceeds from the Company’s ATM facility.Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2024 were $11.3 million, compared with $10.1 million for the third quarter of 2023. The increase in R&D expenses was primarily attributable to higher clinical costs related to the Company’s lead program and increased personnel to support ongoing research and development activities.General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2024 were $4.0 million, compared with $3.9 million for the third quarter of 2023. The increase in G&A expenses was primarily attributable to an increase in the Company’s stock-based compensation costs and employee-related costs in connection with general and administrative functions.Net Loss: Net loss attributable to common stockholders was $14.6 million, or $0.49 per share, for the third quarter ended September 30, 2024, compared to $12.6 million, or $0.43 per share, for the third quarter ended September 30, 2023.2024 Financial Guidance Based on cash, cash equivalents and marketable securities as of September 30, 2024, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into the fourth quarter of 2025.

👍️0

georgie18 3 meses hace

IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

👍️0

Awl416 3 meses hace

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

👍️0

georgie18 3 meses hace

IMRX...$2.13...Still bidding the $1.50 range open gap...Alerted at $1.02 range and ran to $4 range...🥳

👍️0

81vette 3 meses hace

Charting up,demand growing,loading showing,shares to short dropping after big spike

👍️0

TechandBio 4 meses hace

ICCM has superior data with 5 years and counting multiple independent studies compared to any pill or antibody or chemotherapy for a variety of oncology indications.

$IMRX

👍️0

georgie18 4 meses hace

Have a Great Weekend Y'all...🥳

👍️0

herbied47 4 meses hace

Swing idea. AZTR small float, recently received study may proceed letter from the FDA for INDA to treat skin rash from EGFR inhibitors, , recent offering at 1.50, recently announced three newly patents in US, China and Canada to treat inflammatory skin diseases, recent 1/30 reverse split, Maxim Group Buy rating, price target $3

👍️0

georgie18 4 meses hace

👍️0

georgie18 4 meses hace

👍️0

Capitalvaluetrade 4 meses hace

Wowza

👍️0

georgie18 4 meses hace

👍️0

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Immuneering Corporation (IMRX)

Su centro para precios en tiempo real, ideas y debates en vivo

IMRX Noticias

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

Form 8-K - Current report

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Form 4 - Statement of changes in beneficial ownership of securities

Immuneering Launches Pancreatic Cancer Advisory Board

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Form 8-K - Current report

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Form 8-K/A - Current report: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

IMRX Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Immuneering Corporation (IMRX) Noticias

Immuneering Corporation (IMRX)

Su centro para precios en tiempo real, ideas y debates en vivo

IMRX Noticias

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

Form 8-K - Current report

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Form 4 - Statement of changes in beneficial ownership of securities

Immuneering Launches Pancreatic Cancer Advisory Board

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Form 8-K - Current report

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Form 8-K/A - Current report: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

IMRX Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación